CaloSyn Pharma, Inc. is a private biopharmaceutical company developing intra-articular therapeutics for osteoarthritis (OA). The Company’s therapeutic approach is based on proprietary combinations of ion channel modulators (ICMs) which block the synthesis of the enzymes responsible for cartilage destruction. The Company’s key advantages are:
CaloSyn’s first therapeutic target will be OA of the knee. The Company is located in Sharon MA and Shreveport LA.